Aspen Pharmacare Earnings Call: Cash Rich, Margin Stressed

Aspen Pharmacare ((APNHY)) has held its Q2 earnings call. Read on for the main highlights of the call.

Aspen Pharmacare’s latest earnings call painted a mixed but cautiously optimistic picture for investors. Management highlighted robust cash generation and solid momentum in Commercial Pharma, especially in fast-growing GLP‑1 therapies, alongside a major APAC divestment that should radically strengthen the balance sheet. However, a collapse in manufacturing earnings, sterile losses and weaker group profitability underscored execution risks over the next few years.

Free cash flow surges as capex rolls off

Aspen’s cash generation was a bright spot, with cash from operations doubling to ZAR 3.6bn from ZAR 1.8bn. Lower capex, trimmed from ZAR 2.6bn to ZAR 1.6bn, helped deliver roughly ZAR 2bn in free cash flow, supported by better working capital, lower cash finance costs and favorable tax timing.

Commercial Pharma drives growth and margin gains

The Commercial Pharma division continued to underpin the group, posting 4% constant-currency revenue growth and 11% EBITDA growth. Segment EBITDA margin climbed to 29.2% from 28.3%, with all sub‑segments contributing, including 7% growth in Injectables, 2% in Prescription products and expansion in OTC lines.

GLP‑1 franchise accelerates with Mounjaro lead

Aspen is capitalizing on booming demand for GLP‑1 drugs, with the South African market tripling to about ZAR 2.2bn in 18 months. Mounjaro’s market share jumped from 21% to 52%, and management expects sales above ZAR 1.3bn while rolling out in Sub‑Saharan Africa and preparing early semaglutide generic launches in Canada and key emerging markets.

APAC divestment set to de‑lever balance sheet

The pending sale of the APAC portfolio for AUD 237m (over ZAR 25bn in expected net proceeds) is central to Aspen’s value unlock story. With a carrying value of ZAR 21.8bn, the deal should generate an after‑tax profit of roughly ZAR 1.8–2.0bn in H2 and deliver about ZAR 1.2bn in pretax annual interest savings, allowing the company to largely extinguish net debt.

Operational recovery plan targets sterile turnaround

Management reported that around 90% of its reshaping program is complete, with key growth drivers starting to ramp. A new insulin contract is underway and expected to build into FY27, while French sterile facilities have moved from one to six RFQs, with secured volumes seen adding about ZAR 300m in EBITDA by FY27 as Aspen aims to restore sterile profitability.

ESG and access metrics show steady improvement

Beyond financials, Aspen emphasized progress on ESG and access to medicines, with critical medicines volumes rising 8% versus FY24. Women now hold 32% of top leadership roles, up from 19% in FY20, while Scope 1 and 2 emissions are down about 24% from baseline and renewables account for roughly 19% of energy at its facilities.

Manufacturing segment hit by mRNA contract loss

The manufacturing division was the clear weak link, with revenue dropping about 26% in constant currency and EBITDA plunging around 85% to about ZAR 0.2bn. The loss of a large mRNA vaccine contract that contributed roughly ZAR 1.5bn last year, plus a ZAR 500m settlement, produced a near ZAR 1bn negative swing at the EBITDA line.

Group earnings and profitability under pressure

At group level, revenue slipped about 4% to roughly ZAR 21bn and normalized EBITDA fell 13% to about ZAR 5.05bn. Normalized headline earnings per share declined 21% to ZAR 5.75, with management pointing squarely to manufacturing and sterile disruptions as the main drag, despite resilient and expanding Commercial Pharma margins.

Gross margin diluted by weak manufacturing mix

Group gross margin fell from 47.6% to 45.4%, with management flagging a roughly 7% constant-currency deterioration. Commercial Pharma margins remained strong at about 58.5%, implying the overall dilution came from underutilized and loss-making manufacturing assets, especially in steriles, and an unfavorable business mix.

Sterile losses weigh, breakeven targeted by FY27

The sterile business is currently loss-making and a major drag on Aspen’s consolidated performance, even as API profits offset some of the damage above a ZAR 1.7bn threshold. Management’s plan is to use restructuring, new contracts and volume wins to bring sterile EBITDA back to breakeven or better by FY27, restoring its contribution.

ROIC concerns drive renewed capital discipline

Aspen acknowledged that return on invested capital has eroded over time, hurt by write‑downs and underperformance in the manufacturing and sterile units. Improving ROIC is now a stated focus, with the APAC sale, tighter capital allocation and better utilization of existing assets seen as key levers to lift returns to more acceptable levels.

Leverage and macro risks still cloud near term

Net debt remains high at ZAR 28.6bn, albeit down from ZAR 31.2bn, leaving leverage around 3.4x and exposed to currency swings and interest costs. Management also highlighted regulatory and policy uncertainties, from tariffs and vaccine funding to timing of key approvals, as ongoing macro risks until the balance sheet is reset.

Guidance points to H2 recovery and FY27 rebuild

Looking ahead, Aspen is guiding to a stronger second half and FY26, driven by mid‑single‑digit Commercial Pharma revenue growth and double‑digit constant‑currency EBITDA growth. Manufacturing is expected to be broadly in line with last year as lost mRNA contributions are recouped, sterile EBITDA should reach breakeven or better by FY27, normalized HEPS is targeted to grow at least double digits and, with APAC proceeds reducing debt, management aims to restore group EBITDA to about ZAR 9.6bn by FY27.

Aspen’s earnings call ultimately balanced near‑term pain with a clear route to recovery, combining strong cash generation, resilient Commercial Pharma performance and transformational de‑leveraging from the APAC sale. Investors will now focus on whether management can execute on sterile restructuring, manufacturing stabilization and GLP‑1 and insulin opportunities to deliver the promised EBITDA and ROIC rebound over the next three years.